Zoom zoom: Racing CARs for multiple myeloma

Clinical Cancer Research

Volumn 19, Issue 8, 2013, Pages 1917-1919

  Maus, Marcela V ^a   June, Carl H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; B CELL MATURATION ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; APOPTOSIS; B LYMPHOCYTE; CELL ENGINEERING; CELL MATURATION; CELL PROTECTION; CELL SURFACE; CELL THERAPY; CHIMERIC ANTIGEN RECEPTOR T LYMPHOCYTE; CYTOKINE RELEASE; GENETIC ENGINEERING; HUMAN; INTRACELLULAR SIGNALING; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOTOXICITY; MULTIPLE MYELOMA; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANIMALS; B-CELL MATURATION ANTIGEN; HUMANS; MULTIPLE MYELOMA; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84877089027     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0168     Document Type: Note

References (12)

1. Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res 2013;19:2048-60.
2. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33.
3. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012;119:2709-20.
4. Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012;119:3940-50.
5. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011;118:6050-6.
6. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-51.
7. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006;24:e20-2.
8. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold S, et al. Complete remissions of ALL by chimeric antigen receptor-expressing T cells. N Engl J Med. In press 2013.
9. Coquery CM, Erickson LD. Regulatory roles of the tumor necrosis factor receptor BCMA. Crit Rev Immunol 2012;32:287-305.
10. Moreaux J, Sprynski AC, Dillon SR, Mahtouk K, Jourdan M, Ythier A, et al. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. Eur J Haematol 2009;83:119-29.
11. O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004;199:91-8.
12. Jiang C, Loo WM, Greenley EJ, Tung KS, Erickson LD. B cell maturation antigen deficiency exacerbates lymphoproliferation and autoimmunity in murine lupus. J Immunol 2011;186:6136-47.